Mouse anti-Mouse, Human C3/C3b/iC3b Antibody | anti-C3/C3b/iC3b antibody

Anti-Human/Mouse C3/C3b/iC3b, (Purified) (Clone: 6C9) (Mouse IgG1)

Cat. Num. AAA520889

• Reactivity: Mouse, Human
• Applications: Flow Cytometry, Functional Assay, ELISA
• Purity: Purified
• Synonyms: C3/C3b/iC3b; Anti-Human/Mouse C3/C3b/iC3b; (Purified) (Clone: 6C9) (Mouse IgG1); anti-C3/C3b/iC3b antibody

• Host: Mouse
• Reactivity: Mouse, Human
• Isotype: IgG1
• Clone Number: 6C9
• Specificity: C3/C3b/iC3b
• Purity/Purification: Purified

• Applicable Applications for anti-C3/C3b/iC3b antibody: Flow Cytometry (FC/FACS), ELISA(EIA)
• Conjugate: Unconjugated

Flow Cytometry (FC/FACS)

(C57BL/6 mouse thymocytes incubated with rabbit anti-mouse T cells and then incubated with fresh human serum were stained with anti-C3/C3b/iC3b (clone: 6C9) (filled histogram) or mouse IgG1 isotype control (open histogram).)

Related Product Information for anti-C3/C3b/iC3b antibody

The Purified Anti-Human/Mouse Complement Component C3 monoclonal antibody (Clone: 6C9) reacts with human and mouse C3 as well as the breakdown products C3b and iC3b. C3 is the most abundant complement protein in serum. C3 and its cleavage products, C3a and C3b, play a central role in the complement activation cascade. C3b forms an integral part of the C3 and C5 convertases as it promotes complement activation and the subsequent formation of the membrane attack complex. C3a possesses anaphlatoxic as well as various immunoregulatory properties.
Also, C3 has been implicated in developmental and non-imflammatory process such as hematopoiesis, skeletal and vascular development and reproduction.

References

1) Kremmer E, Thierfelder S, Felber E, et al. (1990) Monoclonal antibodies to complement components without the need of their prior purification. II. Antibodies to mouse C3 and C4. Hybridoma. 9(4):309-17. 2) Cortes C, Ferreira VP, Pangburn MK. (2011) Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun. 79(2):724-31. 3) Fridkis-Hareli M, Storek M, Mazsaroff I, et al. (2011) Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood. 118(17):4705-13.